Chen YaoYao, Xu Jiawei, Yu Chengdong, Shi Haoyu, Luo Ling, Peng Dingbang, Zhang Xiaofang, Chen Wen, Le Fei
Jiangxi Medical College, Nanchang University, Nanchang, China.
Department of Pathology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Front Med (Lausanne). 2025 Apr 15;12:1510225. doi: 10.3389/fmed.2025.1510225. eCollection 2025.
Intestinal-type adenocarcinoma (ITAC) of the nasal cavity is a rare, aggressive tumor that presents unique therapeutic challenges, particularly in cases of recurrent disease with intracranial extension. We present the case of a 54-year-old male with recurrent ITAC who demonstrated a remarkable response to a novel triple-therapy approach. This patient lacked the typical risk factors, such as occupational exposure to wood or leather dust, making this case particularly unusual. After failing conventional treatments and experiencing multiple recurrences with progressive intracranial invasion, the patient received an innovative combination of immunotherapy (Toripalimab), targeted therapy (Anlotinib), and chemotherapy (S-1). This unprecedented therapeutic combination resulted in significant tumor volume reduction (from 53.9 × 42.7 mm to 38.9 × 18.8 mm) and marked improvement in neurological symptoms, particularly diplopia. To our knowledge, this represents the first case report of successful implementation of this specific triple therapy regimen for recurrent ITAC with intracranial extension.
鼻腔肠型腺癌（ITAC）是一种罕见的侵袭性肿瘤，带来了独特的治疗挑战，尤其是在疾病复发并伴有颅内扩展的情况下。我们报告了一例54岁复发性ITAC男性患者，其对一种新型三联疗法表现出显著反应。该患者缺乏典型的风险因素，如职业性接触木材或皮革粉尘，使得该病例尤为特殊。在传统治疗失败且经历多次复发并伴有进行性颅内侵犯后，患者接受了免疫疗法（托瑞帕利单抗）、靶向疗法（安罗替尼）和化疗（S-1）的创新联合治疗。这种前所未有的治疗组合使肿瘤体积显著缩小（从53.9×42.7毫米缩小至38.9×18.8毫米），并使神经症状，尤其是复视，得到明显改善。据我们所知，这是首例关于成功应用这种特定三联疗法治疗伴有颅内扩展的复发性ITAC的病例报告。
